サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1566969

ブルセラ病ワクチン市場：タイプ別、ワクチン別、動物タイプ別、エンドユーザー別：世界の機会分析と産業予測、2024～2033年

Brucellosis Vaccines Market By Type , By Vaccine By Animal Type By End User : Global Opportunity Analysis and Industry Forecast, 2024-2033

出版日
ページ情報
英文 280 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
ブルセラ病ワクチン市場：タイプ別、ワクチン別、動物タイプ別、エンドユーザー別：世界の機会分析と産業予測、2024～2033年
出版日: 2024年07月10日
発行: Allied Market Research
ページ情報: 英文 280 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ブルセラ病ワクチン市場は2023年に2億米ドルと評価され、2024～2033年にかけてCAGR 6.4%で成長し、2033年には4億米ドルに達すると予測されています。

ブルセラ病ワクチンは、ブルセラ菌によって引き起こされる人獣共通感染症であるブルセラ病の予防と制御に使用される重要なツールです。この病気はウシ、ヒツジ、ヤギを含む様々な家畜に感染し、流産、繁殖力の低下などの繁殖不全を引き起こし、農業部門に多大な経済的損失をもたらします。ヒトの場合、ブルセラ病はインフルエンザのような軽い症状から重度の慢性症状まで、さまざまな症状を引き起こす可能性があります。家畜へのワクチン接種は、動物からヒトへのブルセラ菌の感染を減少させる要であり、公衆衛生と食の安全において重要な役割を果たしています。

世界のブルセラ病ワクチン市場の成長は、特に農業活動が盛んな地域における家畜のブルセラ病発生率の上昇と、ブルセラ病予防のためのワクチン接種の重要性に対する農業従事者や家畜所有者の意識の高まりによってもたらされています。世界有数の医療研究センターである米国立衛生研究所が発表した調査によると、ブルセラ症は人獣共通感染症の中で最も一般的な病気のひとつで、年間50万人が罹患しています。食肉と乳製品の世界の需要の増加に伴い、ブルセラ症のような病気から家畜を守る必要性が高まり、ブルセラ病ワクチン市場をさらに牽引しています。さらに、ブルセラ症は人畜共通感染症であり、ヒトに感染する可能性があるため、ヒトの健康を守るために家畜の病気をコントロールすることに注目が集まっており、それがワクチン需要を促進しています。さらに、特にブルセラ病が公衆衛生上の重要な問題である国々では、地域や国によるワクチン接種キャンペーンの動向が活発化しており、市場の成長に大きく寄与しています。さらに、ヒト、動物、環境の健康の相互関連性に焦点を当てたワンヘルスのコンセプトの重視が、ブルセラ病ワクチン市場に影響を与えています。この全体論的なアプローチにより、特にブルセラ病が流行している地域では、動物と人間の両方におけるブルセラ病を制圧するための統合的な取り組みが行われています。しかし、新しく効果的なブルセラ病ワクチンの開拓に伴う高コストが、世界市場の成長を妨げています。さらに、遺伝的変異によるブルセラ菌のワクチン耐性株の出現は、既存のワクチンの有効性を低下させ、市場の成長を著しく抑制しています。逆に、より効果的で安全なワクチンの開発など、ワクチン技術の進歩は、疾病対策の有効性を向上させることで市場の成長に寄与しています。さらに、バイオテクノロジーの進歩は、組み換えDNA技術やその他の分子技術の利用など、ワクチン製造における技術革新を促進しています。これらの技術革新により、ブルセラ病ワクチンの有効性と安全性が向上し、より利用しやすく拡大性のあるものになっています。

世界のブルセラ病ワクチン産業は、タイプ、ワクチン、動物タイプ、エンドユーザー、地域に区分されます。タイプ別では、市場はRBS1、S19、B19に分けられます。ワクチン別では、DNAワクチン、サブユニットワクチン、ベクターワクチン、組み換えワクチンに分かれます。動物タイプ別では、ウシ、ヒツジ、ヤギに細分化されます。エンドユーザー別では、動物病院＆クリニック、動物ケアセンター、その他に細分化されます。地域別では、北米、欧州、アジア太平洋、ラテンアメリカ・中東・アフリカで分析されます。

主要調査結果

タイプ別では、RBS1セグメントが2023年の市場シェアを独占しました。

ワクチン別では、DNAワクチンセグメントが2023年の市場の主要株主でした。

動物タイプ別では、牛が2023年の主要セグメントとして浮上しました。

エンドユーザー別では、動物病院・クリニックセグメントが2023年に最大のシェアを獲得しました。

地域別では、北米が2023年に支配的な地位を占めたが、アジア太平洋は予測期間中に最も高いCAGRを記録すると予想されます。

本レポートのカスタマイズの可能性（追加費用とスケジュールが必要です。）

  • 製品/セグメント別市場セグメンテーション
  • 主要企業の新製品開発/製品マトリックス
  • 規制ガイドライン
  • クライアントの関心に応じた追加企業プロファイル
  • 国別または地域別の追加分析-市場規模と予測
  • 企業プロファイルの拡大リスト
  • 過去の市場データ
  • 主要参入企業の詳細（所在地、連絡先、サプライヤー/ベンダーネットワークなどを含む、エクセル形式）

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場情勢

  • 市場の定義と範囲
  • 主要調査結果
    • 主要投資機会
    • 主要成功戦略
  • ポーターのファイブフォース分析
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会

第4章 ブルセラ病ワクチン市場：タイプ別

  • 市場概要
  • RBS1
  • S19
  • B19

第5章 ブルセラ病ワクチン市場：ワクチン別

  • 市場概要
  • DNAワクチン
  • サブユニットワクチン
  • ベクターワクチン
  • 組み換えワクチン

第6章 ブルセラ病ワクチン市場：動物タイプ別

  • 市場概要
  • 牛
  • 羊
  • ヤギ

第7章 ブルセラ病ワクチン市場：エンドユーザー別

  • 市場概要
  • 動物病院とクリニック
  • 動物ケアセンター
  • その他

第8章 ブルセラ病ワクチン市場：地域別

  • 市場概要
  • 北米
    • 主要市場動向と機会
    • 米国のブルセラ病ワクチン市場
    • カナダのブルセラ病ワクチン市場
    • メキシコのブルセラ病ワクチン市場
  • 欧州
    • 主要市場動向と機会
    • ドイツのブルセラ病ワクチン市場
    • フランスのブルセラ病ワクチン市場
    • 英国のブルセラ病ワクチン市場
    • イタリアのブルセラ病ワクチン市場
    • スペインのブルセラ病ワクチン市場
    • その他の欧州のブルセラ病ワクチン市場
  • アジア太平洋
    • 主要市場動向と機会
    • 日本のブルセラ病ワクチン市場
    • 中国のブルセラ病ワクチン市場
    • オーストラリアのブルセラ病ワクチン市場
    • インドのブルセラ病ワクチン市場
    • 韓国のブルセラ病ワクチン市場
    • その他のアジア太平洋のブルセラ病ワクチン市場
  • ラテンアメリカ・中東・アフリカ
    • 主要市場動向と機会
    • ブラジルのブルセラ病ワクチン市場
    • サウジアラビアのブルセラ病ワクチン市場
    • 南アフリカのブルセラ病ワクチン市場
    • その他のラテンアメリカ・中東・アフリカのブルセラ病ワクチン市場

第9章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10企業の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主要企業のポジショニング（2023年）

第10章 企業プロファイル

  • Ceva Poultry
  • Colorado Serum Company
  • Creative Biolabs
  • CZ Vaccines
  • Fivet Animal Health
  • Hester Biosciences Limited
  • Indian Immunologicals Ltd
  • Jordan Bio-industries Center
  • Laboratories Tornel
  • Merck And Co., Inc.
目次
Product Code: A324385

The brucellosis vaccines market was valued at $0.2 billion in 2023, and is projected to reach $0.4 billion by 2033, growing at a CAGR of 6.4% from 2024 to 2033.

Brucellosis vaccine is a critical tool used in the prevention and control of brucellosis, a zoonotic bacterial infection caused by Brucella species. This disease affects various livestock, including cattle, sheep, and goats, leading to reproductive failures such as abortions, reduced fertility, and significant economic losses in the agricultural sector. In humans, brucellosis can cause a range of symptoms, from mild flu-like illness to severe, chronic conditions. Vaccination of livestock is a cornerstone in reducing the transmission of Brucella from animals to humans, thus playing a vital role in public health and food safety.

The growth of the global brucellosis vaccines market is driven by rise in incidence of brucellosis in livestock, particularly in regions with significant agricultural activity, and increase in awareness among farmers and livestock owners about the importance of vaccination in preventing brucellosis. According to a study published by the National Institutes of Health-one of the world's foremost medical research centers-brucellosis is one the most common zoonotic diseases affecting 500,000 cases annually. As the global demand for meat and dairy products grows, there is a corresponding increase in the need to protect livestock from diseases like brucellosis, further driving the brucellosis vaccine market. Moreover, with brucellosis being a zoonotic disease that can be transmitted to humans, there is an increasing focus on controlling the disease in animals to protect human health, which, in turn, fosters the demand for vaccines. Furthermore, increase in trend of regional and national vaccination campaigns, particularly in countries where brucellosis is a significant public health issue, is notably contributing toward the market growth. In addition, emphasis on the One Health concept, which focuses on the interconnectedness of human, animal, and environmental health, is influencing the brucellosis vaccination market. This holistic approach is leading to integrated efforts to control brucellosis in both animals and humans, particularly in regions where the disease is endemic. However, high cost associated with development of new and effective brucellosis vaccines is hampering the growth of the global market. In addition, the emergence of vaccine-resistant strains of Brucella due to genetic variability has reduced the effectiveness of existing vaccines, which significantly restrained the market growth. On the contrary, advancements in vaccine technology, such as the development of more effective and safer vaccines, are contributing to market growth by improving the efficacy of disease control measures. Moreover, advances in biotechnology are driving innovations in vaccine production, including the use of recombinant DNA technology and other molecular techniques. These innovations are enhancing the efficacy and safety of brucellosis vaccines, making them more accessible and scalable.

The global brucellosis vaccines industry is segmented into type, vaccine, animal type, end user, and region. By type, the market is divided into RBS1, S19, and B19. As per vaccine, it is segregated into DNA vaccine, subunit vaccine, vector vaccine, and recombinant vaccine. By animal type, it is fragmented into cattle, sheep, and goat. Depending on end user, it is fragmented into veterinary hospitals & clinics, animal care centers, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By type, the RBS1 segment dominated the market share in 2023.

As per vaccine, the DNA vaccine segment was the major shareholder in the market in 2023.

On the basis of animal type, cattle emerged as the leading segment in 2023.

Depending on end user, the veterinary hospitals & clinics segment garnered the largest share in 2023.

Region wise, North America held the dominant position in 2023; however, Asia-Pacific is expected to register highest CAGR during the forecast period.

Competition Analysis

Competitive analysis and profiles of the major players in the global brucellosis vaccines market include Ceva Poultry, Colorado Serum Company, Creative Biolabs, CZ Vaccines, Fivet Animal Health, Hester Biosciences Limited, Indian Immunologicals Ltd, Jordan Bio-industries Center, Laboratories Tornel, and Merck & Co., Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the global market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Market share analysis of players by products/segments
  • New Product Development/ Product Matrix of Key Players
  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Type

  • RBS1
  • S19
  • B19

By Vaccine

  • DNA Vaccine
  • Subunit Vaccine
  • Vector Vaccine
  • Recombinant Vaccine

By Animal Type

  • Cattle
  • Sheep
  • Goat

By End User

  • Veterinary Hospitals and Clinics
  • Animal Care Centers
  • Other

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Ceva Poultry
    • Colorado Serum Company
    • Creative Biolabs
    • CZ Vaccines
    • Fivet Animal Health
    • Hester Biosciences Limited
    • Indian Immunologicals Ltd
    • Jordan Bio-industries Center
    • Laboratories Tornel
    • Merck & Co., Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: BRUCELLOSIS VACCINES MARKET, BY TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Type
  • 4.2. RBS1
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. S19
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. B19
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country

CHAPTER 5: BRUCELLOSIS VACCINES MARKET, BY VACCINE

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Vaccine
  • 5.2. DNA Vaccine
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Subunit Vaccine
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Vector Vaccine
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country
  • 5.5. Recombinant Vaccine
    • 5.5.1. Key Market Trends, Growth Factors and Opportunities
    • 5.5.2. Market Size and Forecast, By Region
    • 5.5.3. Market Share Analysis, By Country

CHAPTER 6: BRUCELLOSIS VACCINES MARKET, BY ANIMAL TYPE

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Animal Type
  • 6.2. Cattle
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Sheep
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Goat
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country

CHAPTER 7: BRUCELLOSIS VACCINES MARKET, BY END USER

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By End User
  • 7.2. Veterinary Hospitals And Clinics
    • 7.2.1. Key Market Trends, Growth Factors and Opportunities
    • 7.2.2. Market Size and Forecast, By Region
    • 7.2.3. Market Share Analysis, By Country
  • 7.3. Animal Care Centers
    • 7.3.1. Key Market Trends, Growth Factors and Opportunities
    • 7.3.2. Market Size and Forecast, By Region
    • 7.3.3. Market Share Analysis, By Country
  • 7.4. Other
    • 7.4.1. Key Market Trends, Growth Factors and Opportunities
    • 7.4.2. Market Size and Forecast, By Region
    • 7.4.3. Market Share Analysis, By Country

CHAPTER 8: BRUCELLOSIS VACCINES MARKET, BY REGION

  • 8.1. Market Overview
    • 8.1.1 Market Size and Forecast, By Region
  • 8.2. North America
    • 8.2.1. Key Market Trends and Opportunities
    • 8.2.2. Market Size and Forecast, By Type
    • 8.2.3. Market Size and Forecast, By Vaccine
    • 8.2.4. Market Size and Forecast, By Animal Type
    • 8.2.5. Market Size and Forecast, By End User
    • 8.2.6. Market Size and Forecast, By Country
    • 8.2.7. U.S. Brucellosis Vaccines Market
      • 8.2.7.1. Market Size and Forecast, By Type
      • 8.2.7.2. Market Size and Forecast, By Vaccine
      • 8.2.7.3. Market Size and Forecast, By Animal Type
      • 8.2.7.4. Market Size and Forecast, By End User
    • 8.2.8. Canada Brucellosis Vaccines Market
      • 8.2.8.1. Market Size and Forecast, By Type
      • 8.2.8.2. Market Size and Forecast, By Vaccine
      • 8.2.8.3. Market Size and Forecast, By Animal Type
      • 8.2.8.4. Market Size and Forecast, By End User
    • 8.2.9. Mexico Brucellosis Vaccines Market
      • 8.2.9.1. Market Size and Forecast, By Type
      • 8.2.9.2. Market Size and Forecast, By Vaccine
      • 8.2.9.3. Market Size and Forecast, By Animal Type
      • 8.2.9.4. Market Size and Forecast, By End User
  • 8.3. Europe
    • 8.3.1. Key Market Trends and Opportunities
    • 8.3.2. Market Size and Forecast, By Type
    • 8.3.3. Market Size and Forecast, By Vaccine
    • 8.3.4. Market Size and Forecast, By Animal Type
    • 8.3.5. Market Size and Forecast, By End User
    • 8.3.6. Market Size and Forecast, By Country
    • 8.3.7. Germany Brucellosis Vaccines Market
      • 8.3.7.1. Market Size and Forecast, By Type
      • 8.3.7.2. Market Size and Forecast, By Vaccine
      • 8.3.7.3. Market Size and Forecast, By Animal Type
      • 8.3.7.4. Market Size and Forecast, By End User
    • 8.3.8. France Brucellosis Vaccines Market
      • 8.3.8.1. Market Size and Forecast, By Type
      • 8.3.8.2. Market Size and Forecast, By Vaccine
      • 8.3.8.3. Market Size and Forecast, By Animal Type
      • 8.3.8.4. Market Size and Forecast, By End User
    • 8.3.9. UK Brucellosis Vaccines Market
      • 8.3.9.1. Market Size and Forecast, By Type
      • 8.3.9.2. Market Size and Forecast, By Vaccine
      • 8.3.9.3. Market Size and Forecast, By Animal Type
      • 8.3.9.4. Market Size and Forecast, By End User
    • 8.3.10. Italy Brucellosis Vaccines Market
      • 8.3.10.1. Market Size and Forecast, By Type
      • 8.3.10.2. Market Size and Forecast, By Vaccine
      • 8.3.10.3. Market Size and Forecast, By Animal Type
      • 8.3.10.4. Market Size and Forecast, By End User
    • 8.3.11. Spain Brucellosis Vaccines Market
      • 8.3.11.1. Market Size and Forecast, By Type
      • 8.3.11.2. Market Size and Forecast, By Vaccine
      • 8.3.11.3. Market Size and Forecast, By Animal Type
      • 8.3.11.4. Market Size and Forecast, By End User
    • 8.3.12. Rest of Europe Brucellosis Vaccines Market
      • 8.3.12.1. Market Size and Forecast, By Type
      • 8.3.12.2. Market Size and Forecast, By Vaccine
      • 8.3.12.3. Market Size and Forecast, By Animal Type
      • 8.3.12.4. Market Size and Forecast, By End User
  • 8.4. Asia-Pacific
    • 8.4.1. Key Market Trends and Opportunities
    • 8.4.2. Market Size and Forecast, By Type
    • 8.4.3. Market Size and Forecast, By Vaccine
    • 8.4.4. Market Size and Forecast, By Animal Type
    • 8.4.5. Market Size and Forecast, By End User
    • 8.4.6. Market Size and Forecast, By Country
    • 8.4.7. Japan Brucellosis Vaccines Market
      • 8.4.7.1. Market Size and Forecast, By Type
      • 8.4.7.2. Market Size and Forecast, By Vaccine
      • 8.4.7.3. Market Size and Forecast, By Animal Type
      • 8.4.7.4. Market Size and Forecast, By End User
    • 8.4.8. China Brucellosis Vaccines Market
      • 8.4.8.1. Market Size and Forecast, By Type
      • 8.4.8.2. Market Size and Forecast, By Vaccine
      • 8.4.8.3. Market Size and Forecast, By Animal Type
      • 8.4.8.4. Market Size and Forecast, By End User
    • 8.4.9. Australia Brucellosis Vaccines Market
      • 8.4.9.1. Market Size and Forecast, By Type
      • 8.4.9.2. Market Size and Forecast, By Vaccine
      • 8.4.9.3. Market Size and Forecast, By Animal Type
      • 8.4.9.4. Market Size and Forecast, By End User
    • 8.4.10. India Brucellosis Vaccines Market
      • 8.4.10.1. Market Size and Forecast, By Type
      • 8.4.10.2. Market Size and Forecast, By Vaccine
      • 8.4.10.3. Market Size and Forecast, By Animal Type
      • 8.4.10.4. Market Size and Forecast, By End User
    • 8.4.11. South Korea Brucellosis Vaccines Market
      • 8.4.11.1. Market Size and Forecast, By Type
      • 8.4.11.2. Market Size and Forecast, By Vaccine
      • 8.4.11.3. Market Size and Forecast, By Animal Type
      • 8.4.11.4. Market Size and Forecast, By End User
    • 8.4.12. Rest of Asia-Pacific Brucellosis Vaccines Market
      • 8.4.12.1. Market Size and Forecast, By Type
      • 8.4.12.2. Market Size and Forecast, By Vaccine
      • 8.4.12.3. Market Size and Forecast, By Animal Type
      • 8.4.12.4. Market Size and Forecast, By End User
  • 8.5. LAMEA
    • 8.5.1. Key Market Trends and Opportunities
    • 8.5.2. Market Size and Forecast, By Type
    • 8.5.3. Market Size and Forecast, By Vaccine
    • 8.5.4. Market Size and Forecast, By Animal Type
    • 8.5.5. Market Size and Forecast, By End User
    • 8.5.6. Market Size and Forecast, By Country
    • 8.5.7. Brazil Brucellosis Vaccines Market
      • 8.5.7.1. Market Size and Forecast, By Type
      • 8.5.7.2. Market Size and Forecast, By Vaccine
      • 8.5.7.3. Market Size and Forecast, By Animal Type
      • 8.5.7.4. Market Size and Forecast, By End User
    • 8.5.8. Saudi Arabia Brucellosis Vaccines Market
      • 8.5.8.1. Market Size and Forecast, By Type
      • 8.5.8.2. Market Size and Forecast, By Vaccine
      • 8.5.8.3. Market Size and Forecast, By Animal Type
      • 8.5.8.4. Market Size and Forecast, By End User
    • 8.5.9. South Africa Brucellosis Vaccines Market
      • 8.5.9.1. Market Size and Forecast, By Type
      • 8.5.9.2. Market Size and Forecast, By Vaccine
      • 8.5.9.3. Market Size and Forecast, By Animal Type
      • 8.5.9.4. Market Size and Forecast, By End User
    • 8.5.10. Rest of LAMEA Brucellosis Vaccines Market
      • 8.5.10.1. Market Size and Forecast, By Type
      • 8.5.10.2. Market Size and Forecast, By Vaccine
      • 8.5.10.3. Market Size and Forecast, By Animal Type
      • 8.5.10.4. Market Size and Forecast, By End User

CHAPTER 9: COMPETITIVE LANDSCAPE

  • 9.1. Introduction
  • 9.2. Top Winning Strategies
  • 9.3. Product Mapping of Top 10 Player
  • 9.4. Competitive Dashboard
  • 9.5. Competitive Heatmap
  • 9.6. Top Player Positioning, 2023

CHAPTER 10: COMPANY PROFILES

  • 10.1. Ceva Poultry
    • 10.1.1. Company Overview
    • 10.1.2. Key Executives
    • 10.1.3. Company Snapshot
    • 10.1.4. Operating Business Segments
    • 10.1.5. Product Portfolio
    • 10.1.6. Business Performance
    • 10.1.7. Key Strategic Moves and Developments
  • 10.2. Colorado Serum Company
    • 10.2.1. Company Overview
    • 10.2.2. Key Executives
    • 10.2.3. Company Snapshot
    • 10.2.4. Operating Business Segments
    • 10.2.5. Product Portfolio
    • 10.2.6. Business Performance
    • 10.2.7. Key Strategic Moves and Developments
  • 10.3. Creative Biolabs
    • 10.3.1. Company Overview
    • 10.3.2. Key Executives
    • 10.3.3. Company Snapshot
    • 10.3.4. Operating Business Segments
    • 10.3.5. Product Portfolio
    • 10.3.6. Business Performance
    • 10.3.7. Key Strategic Moves and Developments
  • 10.4. CZ Vaccines
    • 10.4.1. Company Overview
    • 10.4.2. Key Executives
    • 10.4.3. Company Snapshot
    • 10.4.4. Operating Business Segments
    • 10.4.5. Product Portfolio
    • 10.4.6. Business Performance
    • 10.4.7. Key Strategic Moves and Developments
  • 10.5. Fivet Animal Health
    • 10.5.1. Company Overview
    • 10.5.2. Key Executives
    • 10.5.3. Company Snapshot
    • 10.5.4. Operating Business Segments
    • 10.5.5. Product Portfolio
    • 10.5.6. Business Performance
    • 10.5.7. Key Strategic Moves and Developments
  • 10.6. Hester Biosciences Limited
    • 10.6.1. Company Overview
    • 10.6.2. Key Executives
    • 10.6.3. Company Snapshot
    • 10.6.4. Operating Business Segments
    • 10.6.5. Product Portfolio
    • 10.6.6. Business Performance
    • 10.6.7. Key Strategic Moves and Developments
  • 10.7. Indian Immunologicals Ltd
    • 10.7.1. Company Overview
    • 10.7.2. Key Executives
    • 10.7.3. Company Snapshot
    • 10.7.4. Operating Business Segments
    • 10.7.5. Product Portfolio
    • 10.7.6. Business Performance
    • 10.7.7. Key Strategic Moves and Developments
  • 10.8. Jordan Bio-industries Center
    • 10.8.1. Company Overview
    • 10.8.2. Key Executives
    • 10.8.3. Company Snapshot
    • 10.8.4. Operating Business Segments
    • 10.8.5. Product Portfolio
    • 10.8.6. Business Performance
    • 10.8.7. Key Strategic Moves and Developments
  • 10.9. Laboratories Tornel
    • 10.9.1. Company Overview
    • 10.9.2. Key Executives
    • 10.9.3. Company Snapshot
    • 10.9.4. Operating Business Segments
    • 10.9.5. Product Portfolio
    • 10.9.6. Business Performance
    • 10.9.7. Key Strategic Moves and Developments
  • 10.10. Merck And Co., Inc.
    • 10.10.1. Company Overview
    • 10.10.2. Key Executives
    • 10.10.3. Company Snapshot
    • 10.10.4. Operating Business Segments
    • 10.10.5. Product Portfolio
    • 10.10.6. Business Performance
    • 10.10.7. Key Strategic Moves and Developments